<DOC>
	<DOCNO>NCT00354120</DOCNO>
	<brief_summary>The purpose study compare Reduced Intensity Conditioning protocols contain either Thymoglobuline Alemtuzumab patient undergo allogeneic transplant voluntary unrelated donor .</brief_summary>
	<brief_title>Thymoglobuline Versus Alemtuzumab Patients Undergoing Allogeneic Transplant</brief_title>
	<detailed_description>The reduction intensity condition currently indicate patient undergo standard myelo-ablation due age , comorbidities type pathology . Furthermore , rationale use RIC regimen base observation infusion alloreactive donor lymphocyte may yield graft versus tumour effect . However , kind regimen morbidity TRM due GvHD still concern vivo T-depletion necessary treatment . Both monoclonal ( Alemtuzumab ) polyclonal T-depletion protocol carry risk benefit . Benefits well prophylaxis GvHD , risk high incidence post-transplantation infection relapse . At moment , clear type regimen , monoclonal polyclonal , good treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Group 1 : 5565 yo patient suffer Acute Myeloblastic Lymphoblastic Leukemia , Myelodisplasia , Chronic Myeloid Leukemia Idiopathic Myelofibrosis ( accord IBMDR operative manual ) Group 2 : patient &lt; = 65 yo suffer lymphoproliferative disease accord REAL classification : Highdoses chemotherapy relapse CLL ( B T ) Follicular lymphoma relapse 2 standard chemotherapy regimens highdoses chemotherapy Mantellar lymphoma relapse 1 standard chemotherapy regimen highdoses chemotherapy Lymphoplasmacytoid B marginal zone lymphoma relapse 2 standard chemotherapy regimens highdoses chemotherapy Advanced ( stage ≥ III A ) relapse T lymphoma Large Bcells lymphomas 2nd complete remission relapse high dose chemotherapy autotransplant 2 standard chemotherapy regimens Fungal mycosis advance stage ( ≥ III A ) chemosensitive relapse 2 line chemotherapy Sezary syndrome chemosensitive relapse 1 line chemotherapy Hodgkin disease relapse autotransplant chemosensitive disease relapse 1 year chemotherapy eligible autotransplant since insufficient mobilization autologous hemopoietic stem cell . Performance status &lt; 70 % ( Karnofsky ) Left ventricular cardiac ejection fraction &lt; 40 % receive treatment heart failure DLCO pulmonary &lt; 40 % receive continuous oxygen therapy Neuropathy ( previous present ) Pregnancy Patients arterial hypertension control multipharmacological treatment HIV positive BCLL clear evidence transformation Richter syndrome Mycosis fungoides clear evidence transformation blast Hodgkin 's disease refractory chemotherapy Absence inform consent Psychiatric disease condition compromise signing informed consent form compliance treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>